Driver-guided Ablation of Persistent Atrial Fibrillatiom

Overview

This is a prospective, single-center, study. A targeted number of 181patients with persistent AF will be included according to pre-defined criteria. The ablation procedure consists on the identification of the arrhythmic substrate using a novel integrated mapping technique. We hypothesize that such approach may potentially lead to a mechanisms-targeted ablation strategy of persistent AF.

Full Title of Study: “Driver-guided Ablation in the Treatment of Persistent Atrial Fibrillation”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: September 28, 2023

Detailed Description

This is a prospective, single-center, study enrolling a total of 181patients with persistent AF according to well defined inclusion and exclusion criteria. The ablation procedure consists on the identification of the arrhythmic substrate using a novel integrated 3D mapping technique followed by standard CPVA at the end of the procedure. We will ablate substrates showing fast and regular electrical activities, starting from areas with the fastest mean cycle length and/or areas that have consistent rotational or focal propagation pattern and/or areas that comprise the slow conduction zone of possible arrhythmia circuits. After substrate ablation and AF termination, arrhythmia inducibility will be assessed and, if not inducible, the procedure will be completed by standard CPVA. If AF is still inducible, a new 3D map will be performed to identify further targets to be eliminated. Electrical cardioversion may be done at the end of the procedure. We hypothesized that such approach may potentially lead to a mechanisms-targeted ablation strategy leading to elimination of arrhythmic sources in individual patients, thus improving their clinical outcome. We will also characterize, identify and target the real pathophysiological substrates. After ablation, AF recurrence will be assessed by implantable loop recorder or thans-telephonic ECG recording from the end of the 3 months blanking period to 12 months following the procedure.The duration of this study is expected to be 24 months, from the first patient enrollment to the last patient follow-up.

Interventions

  • Procedure: Catheter ablation
    • Driver-guided catheter ablation of persistent atrial fibrillation

Clinical Trial Outcome Measures

Primary Measures

  • Freedom from any AF or atrial tachycardia assessed from the end of the months blanking period to 12 months after ablation.
    • Time Frame: 12 months after ablation
    • AF recurrences will be documented by implantable loop recorder or trns-telephonic ECG recording

Secondary Measures

  • Identification of electrophysiological substrate
    • Time Frame: during the procedure
    • Areas with fast but regular activities or with consistent wave front propagation pattern, or with low P-P voltage, or complex fractionated electrograms
  • inducibility of AF after the procedure
    • Time Frame: during the procedure
    • programmed atrial stimulation before and after isoproterenol
  • AF burden
    • Time Frame: 12 months after ablation
    • Assessment of AF burden by trans-telephonic ECG recording or implantable loop recorder

Participating in This Clinical Trial

Inclusion Criteria

Age (18-85 years), persistent AF according to ESC/EHRA guidelines, first or second ablation procedure, ability to provide informed written consent. - Exclusion Criteria:

Secondary AF, Hyperthyroidism, LVEF<30%, NYHA functional class IV, uncorrected valvular heart diseases, contraindication to anticoagulation, left atrial thrombus, recent (<6 months) myocardial infarction, thoracic surgery for congenital, valvular diseases, History of cerebrovascular events, pregnancy, cancer or other significant comorbidities. -

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • IRCCS Policlinico S. Donato
  • Provider of Information About this Clinical Study
    • Principal Investigator: Carlo Pappone, Director – IRCCS Policlinico S. Donato
  • Overall Official(s)
    • Carlo Pappone, MD, Principal Investigator, IRCCS San Donato University Hospital Policlinico San Donato, Milan, Italy
  • Overall Contact(s)
    • Carlo Pappone, MD, +39 02 52774260, carlo.pappone@af-ablation.org

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.